Nektar Therapeutics (NKTR) Cash & Equivalents (2010 - 2026)

Nektar Therapeutics' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $149.6 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 284.58% year-over-year to $149.6 million; the TTM figure through Mar 2026 stood at $149.6 million (up 284.58% YoY), while the FY2025 annual figure was $15.1 million, down 65.84% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $149.6 million, up from $15.1 million in the prior quarter.
• The five-year high for Cash & Equivalents was $149.6 million in Q1 2026, with the low at $15.1 million in Q4 2025.
• The 5-year median for Cash & Equivalents is $48.6 million (2024), against an average of $59.2 million.
• The sharpest annual moves came in 2025 and 2026: Cash & Equivalents plunged 65.84% in 2025, then surged 284.58% in 2026.
• Nektar Therapeutics' Cash & Equivalents stood at $88.2 million in 2022, then plunged by 60.02% to $35.3 million in 2023, then gained by 25.44% to $44.3 million in 2024, then plunged by 65.84% to $15.1 million in 2025, then soared by 889.53% to $149.6 million in 2026.
• Business Quant data shows NKTR's Cash & Equivalents at $149.6 million in Q1 2026, $15.1 million in Q4 2025, and $41.0 million in Q3 2025.